Vaccinating High-Risk Pediatric Patients and Their Families in the Hospital Setting: Give It a Shot!

1060. Persistence of Bactericidal Activity at 4 Years After 2 Primary Doses of a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults Terry Nolan, MBBS PhD; Hartley Garfield, MD; Anil Gupta, MD CCFP; Murdo Ferguson, MBChB; Helen Marshall, MD MBBS; Diego D’Agostino, MSc and Daniela Toneatto, MD; University of Melbourne and Murdoch Children’s Research Institute, Melbourne, Victoria, Australia, University of Toronto, Toronto, ON, Canada, Colchester Research Group, Truro, NS, Canada, University of Adelaide and Women’s and Children’s Hospital, Adelaide, South Australia, Australia, GSK, Amsterdam, Netherlands, GSK, Siena, Italy